Over the past year, Exploration of Targeted Anti-tumor Therapy has achieved an increasing impact and larger number of citations. We sincerely thank everyone's great support! At the beginning of 2023, we are thrilled to announce and recognize the winners of "Highly Cited Paper Award 2022" to show our appreciation to those authors.

Criteria for selection and award:

● Original Articles and Reviews published in 2020-2022;

● Both regular and special issue submissions are considered;

● Citations are counted according to Web of Science (WOS) in 2022;

● Prize for the author team: 300-1,000 USD, certificate of "Highly Cited Paper Award";

● Prize for the corresponding Guest Editor(s): 100-300 USD.

Winning Papers:

★Current strategies for the design of PROTAC linkers: a critical review

  Robert I. Troup, Charlene Fallan*, Matthias G. J. Baud*

  Special Issue: Proteolysis Targeting Chimera (PROTAC)

★The impact of tumour pH on cancer progression: strategies for clinical intervention

  Carol Ward, James Meehan, Mark E Gray, Alan F Murray, David J Argyle, Ian H Kunkler, Simon P Langdon*

★The clinical advances of proteolysis targeting chimeras in oncology

  Hao Xie*, Junjia Liu, Diego M. Alem Glison, Jason B. Fleming

  Special Issue: Proteolysis Targeting Chimera (PROTAC)

Congratulations! We believe these articles will be more shining in the future.

In the following year, we will continue to set "Highly Cited Paper Award" to recognize the related authors. On behalf of the Editorial Board and Editorial Office, we warmly welcome more outstanding researchers to participate in and contribute to the journal. Our thriving journal is always open to you!

After scientific quality review and technical evaluation, our journal Exploration of Targeted Anti-tumor Therapy (ETAT) has been officially accepted for PubMed Central (PMC) on 17 August! We are thrilled that this pivotal moment has reached after only two years since launched. All articles since its inception in 2020 will be accessible as soon as article uploading is completed.

The PMC archive of biomedical and life sciences journal literature is a valuable and respected resource provide through the courtesy of US National Institutes of Health's National Library of Medicine. The content of PMC is fully searchable via the PubMed search engine. Access to articles indexed in PMC is free to scholars throughout the world. While ETAT is already indexed in DOAJ and Scopus, achieving a list in PMC matches our priority to give authors maximum visibility.  In the meantime, ETAT will continue to maintain its Free Publication policy, keeping to improve the publication quality.

ETAT appreciates the enthusiastic support and dedicated work by its editorial board members, guest editors, reviewers, authors and readers. The team has worked hard to ensure that papers already published in ETAT represent high quality research in the field of cancer research, and strives to achieve even higher standards in the future so as to become a leading journal in the domain of cancer research.

Latest progress on September 1, 2022:

All ETAT articles since its inception are accessible on PMC: https://www.ncbi.nlm.nih.gov/pmc/journals/4277/

We are happy to announce that ETAT's application for Scopus has been approved. Within one month, ETAT journal will be listed in the Scopus Title list. 

This is a great embodiment of ETAT's rapid development in just two years since launched, and an important step in being acknowledged as a valuable academic publication. 

We appreciate all Editors, board members, authors, reviewers, and everyone who has contributed to this.

We are very glad to announce the first milestone in 2022. Exploration of Targeted Anti-tumor Therapy (ETAT) is now a member of Committee on Publication Ethics (COPE, https://publicationethics.org/)! It signifies that ETAT journal upholds the highest ethical standards and norms. The journal details can be found at: https://publicationethics.org/members/exploration-targeted-anti-tumor-therapy

This recognition will provide the most substantial encouragement for ETAT's future development. We really appreciate the efforts of our Editors-in-Chief, Board Members, Guest Editors, authors and reviewers.

At the beginning of the New Year, Exploration of Targeted Anti-tumor Therapy is pleased to announce the “Highly Cited Paper Award” to recognize the most highly cited papers in 2020-2021, and to show our appreciation to those authors. 

Eligibility for the awards:
– Original research articles and reviews published in 2020 and 2021;
– Both regular and Special Issue submissions will be considered;
– Citations will be counted according to Web of Science in 2020 and 2021.

After careful evaluation, six articles have been selected, and the author teams will be awarded $1000, $600 and $300 respectively. The authors will also receive a “Highly Cited Paper Award” certificate issued by the journal. In addition, the corresponding Guest Editor will also be awarded $300, $200 and $100 respectively.

1st Prize:
★Current strategies for the design of PROTAC linkers: a critical review
Robert I. Troup, Charlene Fallan*, Matthias G. J. Baud*
Special Issue: Proteolysis Targeting Chimera (PROTAC)

2nd Prize:
★The impact of tumour pH on cancer progression: strategies for clinical intervention
Carol Ward, James Meehan, Mark E Gray, Alan F Murray, David J Argyle, Ian H Kunkler, Simon P Langdon*

★Implementation of an NGS panel for clinical practice in paraffin-embedded tissue samples from locally advanced and metastatic melanoma patients
Paola Castillo, Marta Marginet, Pedro Jares, Mireia García, Elena Gonzalvo, Ana Arance, Adriana García, Llucia Alos, Cristina Teixido*

3rd Prize:
★Potential of guggulsterone, a farnesoid X receptor antagonist, in the prevention and treatment of cancer
Sosmitha Girisa, Dey Parama, Choudhary Harsha, Kishore Banik, Ajaikumar B. Kunnumakkara*
Special Issue: Targeting Transcription Factors for Cancer Therapy

★Role of liquid biopsy for thoracic cancers immunotherapy
Raimondo Di Liello*, Flora Cimmino, Soraya Simón, Emilio Francesco Giunta, Vincenzo De Falco, Paloma Martín-Martorell
Special Issue: Liquid Biopsy in Thoracic Cancer

★Development of PROTACs to address clinical limitations associated with BTK-targeted kinase inhibitors
Rachael Arthur, Beatriz Valle-Argos, Andrew J. Steele, Graham Packham*
Special Issue: Proteolysis Targeting Chimera (PROTAC)

Congratulations to these authors! On behalf of the Editorial Board and Editorial Office, we sincerely appreciate the great supports they provided to this new journal at its early stage. In the following year, we will continue to set the Highly Cited Paper Award to recognize authors who contribute high-quality publications to the journal. Meanwhile, we warmly welcome more outstanding experts to join us and make this journal to be an influential one in the cancer research field.

We are very pleased to share one exciting news! From November 22, 2021, Open Exploration Publishing Inc. is now official members of OASPA – the Open Access Scholarly Publishing Association. It represents the very best in open access publishing and enjoys a high reputation in the publishing industry. View Open Exploration's membership profile page, here: https://oaspa.org/member/open-exploration-publishing-inc/

As a journal of Open Exploration, Exploration of Targeted Anti-tumor Therapy provides immediate open access to all published content; all content is freely available without charge to users or their Institutes. Launched in 2020, this peer-reviewed online journal, now is indexed by CAS, DOAJ, WorldCat, CNKI Scholar, Portico, ResearchGate, etc. A total of 60 quality articles have been published online and these articles have received extensive attention, based on views/downloads/citations. We are very delighted to be joining this community of open access. With this high recognition, we are confident to make great progress in the next stage of journal development. Welcome your attention: https://www.explorationpub.com/Journals/etat

We are pleased to announce that Exploration of Targeted Anti-tumor Therapy has been accepted for indexing in Chemical Abstract Services (CAS). 

CAS is a division of the American Chemical Society. It is the most authoritative and comprehensive source for chemical information. CAS intends to help scientists benefit from the published work of their colleagues around the world by monitoring, abstracting and indexing the world's chemistry-related literature.

We are pleased to announce that Exploration of Targeted Anti-tumor Therapy is now indexed in the Directory of Open Access Journals (DOAJ), an online directory that indexes and provides access to quality open access, peer-reviewed journals. The official website of ETAT on DOAJ is https://doaj.org/toc/2692-3114

Launched in 2020, this fully Open Access cancer research journal continues to grow in scope and influence. Find out more about the journal: https://www.explorationpub.com/Journals/etat

Lately, Open Exploration joined the Initiative for Open Abstracts (I4OA) and fully support "the unrestricted availability of the abstracts of the world's scholarly publications in trusted repositories where they are open and machine-accessible". Read more about it, https://www.explorationpub.com/oep/index/17.

In October and November 2020, three well-known researchers have officially joined the Editorial Board of ETAT. They are Prof. Gareth J. Thomas, Dr. A. Emre Sayan from University of Southampton, UK, and Prof. Miguel Vicente-Manzanares from Instituto de Biologia Molecular y Celular del Cancer (CSIC), Spain. We greatly welcome their participation, and hope they will find the meaning and reward of the Editorial roles in this growing journal. Learn more about ETAT editorial board, https://www.explorationpub.com/Journals/etat/Editorial_Board.

We are very pleased to release the news that six outstanding experts in the field (mainly from genetics, lymphoma, neuro oncology, gynecological oncology, liver cancer, etc.) have joined the Editorial Board of ETAT journal since August 2020. Their recognition and support will be always remembered and appreciated greatly. We warmly welcome their participation and look forward to developing the journal to the next level together.

Associate Editors:

Prof. Francesco Bertoni, MD

Head of Lymphoma Genomics, deputy director of Institute of Oncology Research, Faculty of Biomedical Sciences, USI, Bellinzona, Switzerland. Vice-president of SAKK Project Group Lymphoma.

Prof. Antonio Giordano, MD, PhD

Present Professor, Department of Biology and Medicine; Present Director, Sbarro Health Research Organization; Present Director, Center of Biotechnology; Present Director, Professional Master Program (PSM) in Bioinnovation; Temple University, Philadelphia, PA, USA. Present “Chiara Fama” Professor, Department of Medical Biotechnology, University of Siena, Italy.

Prof. Chunsheng Kang, MD, PhD

Deputy Director of Tianjin Neurology Institute, Director of neuro-tumor laboratory of Tianjin Medical University General Hospital, Tianjin, China. Vice Chairman of Glioma Committee of the Chinese Medical Doctor Association, Chairman of the 2nd Basic and Transfer Chemistry Group, and Permanent Member of Glioma Committee of the Chinese Anti-Cancer Association.

Prof. Maurie Markman, MD

President, Cancer Treatment Centers of America Medicine & Science; Chief Clinical Officer, CTCA Health, Philadelphia, PA, USA.

Prof. Massimo Di Maio, MD

Director, Division of Medical Oncology, A.O. Ordine Mauriziano; Associate Professor of Medical Oncology, Department of Oncology, University of Turin, Torino, Italy.

Editorial Board Member:

Prof. Lorenza Rimassa, MD

Associate Professor of Medical Oncology, Department of Biomedical Sciences, Humanitas University; Deputy Director, Medical Oncology Unit, Humanitas Cancer Center, Humanitas Research Hospital, IRCCS, Milano, Italy. Member of the Italian Association of Medical Oncology (AIOM), the European Society for Medical Oncology (ESMO), the American Society of Clinical Oncology (ASCO), the European Association for the Study of the Liver (EASL), and the International Liver Cancer Association (ILCA).

Exploration of Targeted Anti-tumor Therapy always endorses and applies the standards and recommendations of the ICMJE, to ensure the rigorousness of review and publication process. Now, the journal has been recognized in the list of "Journals stating that they follow the ICMJE Recommendations". Learn more about the information via http://www.icmje.org/journals-following-the-icmje-recommendations/.